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Abstract
Background: Kallikrein 15 (KLK15)/Prostinogen is a plausible candidate for prostate cancer susceptibility. Elevated KLK15
expression has been reported in prostate cancer and it has been described as an unfavorable prognostic marker for the
disease.
Objectives: We performed a comprehensive analysis of association of variants in the KLK15 gene with prostate cancer risk
and aggressiveness by genotyping tagSNPs, as well as putative functional SNPs identified by extensive bioinformatics
analysis.
Methods and Data Sources: Twelve out of 22 SNPs, selected on the basis of linkage disequilibrium pattern, were analyzed
in an Australian sample of 1,011 histologically verified prostate cancer cases and 1,405 ethnically matched controls.
Replication was sought from two existing genome wide association studies (GWAS): the Cancer Genetic Markers of
Susceptibility (CGEMS) project and a UK GWAS study.
Results: Two KLK15 SNPs, rs2659053 and rs3745522, showed evidence of association (p,0.05) but were not present on the
GWAS platforms. KLK15 SNP rs2659056 was found to be associated with prostate cancer aggressiveness and showed
evidence of association in a replication cohort of 5,051 patients from the UK, Australia, and the CGEMS dataset of US
samples. A highly significant association with Gleason score was observed when the data was combined from these three
studies with an Odds Ratio (OR) of 0.85 (95% CI=0.77–0.93; p=2.7610
24). The rs2659056 SNP is predicted to alter binding
of the RORalpha transcription factor, which has a role in the control of cell growth and differentiation and has been
suggested to control the metastatic behavior of prostate cancer cells.
Conclusions: Our findings suggest a role for KLK15 genetic variation in the etiology of prostate cancer among men of
European ancestry, although further studies in very large sample sets are necessary to confirm effect sizes.
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Introduction
Prostate cancer is the most common cancer (after skin cancers)
in the Western world with one in nine men expected to develop
prostate cancer by the age of 75 and 20,000 new cases being
diagnosed annually in Australia (Prostate Cancer Foundation of
Australia, http://www.prostate.org.au, 2010). Age, race and
family history of prostate cancer are well-established risk factors
for prostate cancer [1]. In addition, there is considerable evidence
for a genetic basis underlying risk for prostate cancer [2,3]. The
chromosomal region 19q12-13 is of considerable interest, as
previous gene and protein expression studies have shown this
region to harbor both prostate cancer susceptibility and aggres-
siveness loci [4,5,6,7]. The human Kallikrein (KLK) gene family
comprises 15 genes and is clustered together in a small region of
approximately 320 kb at chromosome 19q13.4 [7,8,9]. KLK15
(also called Prostinogen) is the most recently cloned member of the
human Kallikrein gene family and is adjacent to KLK3/prostate
specific antigen (PSA) in genetic location [10,11]. KLK15 has been
reported to be upregulated at the mRNA level in prostate cancer
[11,12,13] and has been described as an unfavorable prognostic
marker for prostate cancer progression following radical prosta-
tectomy [14]. KLK15 has also been reported to be a significant
predictor of reduced progression-free survival and overall survival
in ovarian cancer [15] and a favorable prognostic marker for
breast cancer [16].
Studies of KLK genetic variants and their association with cancer
have increased in the last few years with the aim to better
understand the biology of cancers and to develop potential new
targets for genetic testing with regard to cancer risk and prognostic
value [6,10,17,18,19,20,21,22]. Recently, genome-wide associa-
tion studies (GWAS) have identified a number of single nucleotide
polymorphisms (SNPs) that are associated with risk of developing
prostate cancer. One of these hits, rs2735839, is close to the KLK3
(PSA) gene [23,24]. There is some debate as to whether the SNP is
associated with prostate cancer or simply correlates with PSA
expression levels, as controls used for stage 1 of this GWAS were
limited to those with low PSA levels (,0.5 ng/ml) [19,23].
However, these results were replicated in studies with PSA
unselected controls, including our study group [23], signifying the
importance of this region in prostate cancer. Specifically since
KLK15 is located adjacent to KLK3, and shows altered expression
in prostate cancer, it is a very plausible candidate prostate cancer
gene.
Although some KLK15 SNPs have been genotyped in GWAS,
the large majority of variation in the KLK15 gene remains
unexplored for an association with prostate cancer. Investigation
of a number of public databases, including NCBI Entrez-dbSNP
(http://www.ncbi.nlm.nih.gov/entrez/db=snp), reveals the above-
mentioned GWAS platforms cover from approximately 6–55% of
validated variation in the KLK genes (Lose, Batra et al, unpublished
data, 2010). These observations prompted us to undertake an
association study between twenty-two KLK15 SNPs, identified
through in silico and sequencing approaches, with the risk of prostate
cancer in a large group of Australian men with prostate cancer and
male controls not screened for PSA levels. SNPs found to be
associated with prostate cancer risk and/or aggressiveness were also
assessedusingGWASdatafromadditionalreplicationdatasetsinthe
UK, Australia [24] and USA [25].
Results
In silico analysis, KLK15 promoter sequencing and
Linkage Disequilibrium mapping
We have used in silico prediction of function of wildtype and
variant promoter sequences through assessment of hormone
receptor elements and transcription factor binding sites; as well
as prediction of likely splice variants through genomic, splicing and
EST databases and web sites, and multiple sequence alignment
packages as described previously [26]. We sequenced germline
DNA from 20 aggressive prostate cancer patients (Gleason score
.7) within the putative KLK15 promoter and detected 20 SNPs (6
of which were classified as not validated by NCBI database at the
time of data generation). Seven non-validated SNPs from the
NCBI database were found to be non-polymorphic in our
sequencing cohort. Further, we identified two novel SNPs, but
neither was predicted in silico to have a functional role and hence
was not considered for further genotyping.
SNPs chosen for genotyping in this study were (i) identified as
tagging SNPs using HapMap version 22 (April 07), using a minor
allelefrequency.0.05andpairwise linkage disequilibriumthreshold
of r
2.0.8 (rs2659058, rs3212810, rs3745522, rs2659056, rs266851,
rs2163861, rs266856), or (ii) chosen due to the in silico prediction of a
functional effect on KLK15 expression (rs3212853, rs3212852,
rs16987576, rs2659055, rs266853, rs266854, rs190552, rs266855,
rs2739442, rs2033496, rs12978902, rs2659053, rs2569746,
rs35711205, rs2569747) (Table S1). As the frequency data for many
oftheseSNPswasnotavailable,we genotyped all 22SNPsin.1000
male controls and generated a linkage disequilibrium (LD) map
using Haploview 4.2 (Figure S1). All SNPs except rs3745522 were
found to follow Hardy–Weinberg Equilibrium (p,0.01) (Table S1).
SNP rs12978902 was non-polymorphic, while rs3212853,
rs3212852, rs16987576, rs266853 and rs266854 were found to
have minor allele frequencies ,0.05 (Table S1), so were not
pursued further for the association analysis. SNPs in high LD
with other SNPs (r
2.0.9; rs2163861, rs266856, rs2033496,
rs2569747) were also not analysed further. Priority was given to
putative functional SNPs, with a total of 12 SNPs shortlisted for
further genotyping in Australian prostate cancer patients and
controls (Table S1).
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aggressiveness
Initially DNA from 1,011 men recently diagnosed with prostate
cancer and 1,405 male controls from Queensland (QLD),
Australia, were analysed in this study. Table 1 illustrates a number
of the socio-demographic and clinical characteristics of the QLD
sample set studied. For specific SNPs where replication was
sought, a maximum of 10,685 prostate cancer cases and 12,515
matched controls from UK, Australia and USA were included in
the study.
When twelve of the KLK15 SNPs were assessed individually
(Table S2) in the Australian sample set, two were found to be
marginally associated with risk of prostate cancer (Table 2), neither
of which has data available from existing UK GWAS and
CGEMS sample sets. The age adjusted OR for rs2659053 was
1.25 (95% CI=1.04–1.50; p=0.050) for the GA genotype
compared to the wildtype GG genotype. The CG genotype of
rs35711205 displayed an OR of 1.27 (95% CI=1.06–1.52;
p=0.027) compared to the common CC genotype (Table 2). To
obtain more comparable age distributions, we reanalyzed our data
excluding all controls younger than the youngest case (i.e. all
controls less than 43 years, N=70) and similar results were
obtained for both of these SNPs (rs2659053: OR=1.25, 95%
CI=1.05–1.51, rs35711205: OR=1.28, 95% CI=1.07–1.53).
We also observed a similar result when case-control analysis was
restricted to Caucasian subjects (data not shown) or when analyses
included aggressive patients only (Gleason score$7) (Supplemen-
tary Table S2). These SNPs were not found to be significantly
associated with prostate cancer risk in a recently published study,
where results were imputed from nextgen sequencing data and
PLCO study group from CGEMS dataset, Table 2 [27].
KLK15 SNP rs2659056 was found to be associated with risk of
prostate cancer in UK stage 1 GWAS only, with OR=2.01 (95%
CI=1.50–2.68; p=5.45610
27), but was not found to be
significantly associated with prostate cancer risk in the QLD
dataset (OR=1.16, 95% CI=0.83–1.62; p=0.41) or the PLCO
study group from CGEMS dataset (OR=0.95, 95% CI=0.68–
1.33; p=0.94) (Table S2).
Analysis of the association of rs2659056 with Gleason scores
using case-case analysis of the QLD dataset revealed a significant
association (Table 3). The C allele was significantly more common
in patients with less aggressive disease compared to patients with
more aggressive disease with per allele OR=0.70, 95% CI=0.56–
0.89; p=0.003) (Table 4). Analysis of this SNP in the available
replication sets showed evidence for association in the UK stage 3
dataset (OR=0.87, 95% CI=0.78–0.98; p=0.020) and the
results were in the same direction for the CGEMS dataset
(OR=0.93, 95% CI=0.77–1.12; p=0.43) but not the other 2
studies (Table 4; Figure S2). The combined estimates for all 5
studies was OR=0.92 (95% CI=0.86–0.98), but with significant
evidence of heterogeneity (p=0.023). The heterogeneity of the
ORs was minimized when we restricted our combined analysis to
the QLD, UK GWAS stage 3 and CGEMS datasets (heteroge-
neity p=0.86). Utilizing these three datasets, a combined OR of
0.85 (95% CI=0.77–0.93; p=2.7610
24) was observed for
rs2659056.
Discussion
In the current study, 12 SNPs were genotyped in 1,011
Australian prostate cancer cases and 1,405 male controls from an
initially chosen set of 22 SNPs (7 tag SNPs from the HapMap and
15 SNPs selected on the basis of in silico analysis). Two SNPs,
rs2659053 and rs35711205, present in the putative promoter
region of KLK15 gene (both upstream of exon ‘‘A’’) [26], showed
evidence of an association with risk of prostate cancer. However,
in a recent study, of 1,179 cases and 1,124 control subjects,
published by Parikh et al, these two SNPs were not found to be
significantly associated with risk of prostate cancer from imputed
data from the PLCO cohort [27]. Although this might suggest that
Table 1. Socio-demographic and clinical characteristics of the
QLD study populations.
Characteristics
Men with prostate
cancer (n=1011)
n (%)
Healthy controls
(n=1405) n (%)
Age in years (median, range) 64 (43–88) 62 (18–75)
BMI (Mean, SD) 24.3 (11.6) 26.5 (7.3)
Marital status
Never married 40 (4) 101 (7)
Married/de facto 847 (84) 1124 (80)
Divorced/separated/widowed 118 (11) 161 (12)
Unknown 6 (1) 25 (1)
Family history of prostate cancer
a
No 722 (72) 1253 (89)
Yes 286 (28) 151 (11)
Vasectomy status
b
No 109 (72) 847 (62)
Yes 43 (28) 521 (38)
Smoking status
Never smoked
c 404 (40) 596 (42)
Former smoker 527 (52) 751 (54)
Current smoker 78 (8) 37 (3)
Unknown 2 (0) 21 (2)
Alcohol consumption
b
Non-drinker 57 (38) 180 (13)
Drinker 95 (62) 1207 (87)
Highest education level achieved
No formal education/primary
school
139 (14) 245 (17)
Secondary school 361 (36) 330 (24)
Technical college 321 (32) 447 (32)
University 180 (17) 365 (26)
Unknown 10 (1) 18 (1)
Self reported Serum PSA levels
,4 ng/ml 119 (12) Not measured
4–10 ng/ml 526 (52) Not measured
.10 ng/ml 249 (24) Not measured
Unknown 126 (12) Not measured
Gleason score (Gleason grade 1+Gleason grade 2)
,7 231 (23) Not applicable
$7 559 (55) Not applicable
Unknown 221 (22) Not applicable
apositive family history is defined as at least one first degree relative with
prostate cancer.
bData was not collected for the retrospective study. Study characteristics
differed significantly between cases and controls (P,0.01).
cSmokers are people who smoked at least 100 cigarettes in their entire life.
doi:10.1371/journal.pone.0026527.t001
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knowledge these SNPs have not been directly genotyped in
previous GWAS [28] [25] or candidate gene association studies
focused on the Kallikrein locus [19] and hence need replication in a
bigger sample set.
The KLK15 tagSNP rs2659056 was found to be significantly
associated with risk of prostate cancer only in the UK GWAS stage
1 dataset, but in no other datasets. This may possibly be due to
different patient and control selection criteria. Specifically, the UK
GWAS stage 1 controls [24] were selected by design for low PSA
(,0.5 ng/ml) and no limitations were placed on case-group PSA
values, while stage 2 and stage 3 UK GWAS datasets, demonstrat-
ing attenuated risk estimates, had less stringent selection of controls
(PSA levels of ,10 and requiring a negative prostatic biopsy if the
PSA was .4). In addition, QLD and CGEMS samples showing no
association with risk had no selection of controls by PSA. In support
of this explanation, the control allele frequency in the UK stage 1
dataset differs in comparison to the other datasets (p=0.0001).
Interestingly, we found a significant association of the same SNP
withprostate canceraggressiveness inour QLDstudycohort.There
was no genotypic association between the rs2659056 SNP and
various other clinical markers in healthy men, including serum
vasectomy(p=0.89),and alcohol consumption(p=0.30),thusthese
clinical variables are not confounding our results. There was
evidence for replication in the UK GWAS stage 3 dataset of more
than 3,000 patients from UK and Australia and the CGEMS study
of ,1,000US patients fortheassociation of the rs2659056SNPand
prostate cancer aggressiveness, but not in the UK GWAS stage 1
and stage 2 datasets, with significant heterogeneity observed across
the datasets driven by the UK GWAS stage 1 and stage 2 dataset.
Thisheterogeneity may be explained in part by differences in tumor
grading systems by urologists in different countries, as well as by
different patient recruitment criteria for the different sample sets -
for example, the Australian patient samples were pathology-
confirmed patients who presented with symptomatic disease, whilst
the UK GWAS stage 1 samples were detected by PSA screening
and were also enriched for early onset disease or patients with
familial history of prostate cancer. This interesting finding would
benefit from further replication in very large consortium sample
sets, such as those of PRACTICAL (Prostate cancer association
group to investigate cancer associated alterations in the genome
consortium).
SNP rs2659056 was selected as a HapMap tagSNP, but is
located in a gene regulatory region ,400 bps downstream of a
newly identified KLK15 exon [26]. It was thus assessed for a
possible causal effect on transcription factor binding affinities to
investigate if it might alter KLK15 gene expression via this
mechanism. The TFSEARCH (http://www.cbrc.jp/research/
db/TFSEARCH.html) database indicated that an A to G change
in the rs2659056 increases scores for binding of the orphan
nuclear receptor RORalpha, which has been shown to be involved
in the control of cell growth and differentiation, along with the
control of metastatic behavior of androgen-independent prostate
cancer cells [29]. Thus, the association of rs2659056 SNP with
prostate cancer aggressiveness, if confirmed in larger studies,
would prioritize rs2659056 SNP itself as possible causative SNP.
In line with our results, Parikh et al recently identified significant
associations between KLK3 SNPs in nonaggressive prostate cancer
only [27]. Our results and that of Parikh et al suggest that the risk
effects observed in the PSA locus may reflect the increased
identification of men with clinically insignificant and non-life
threatening prostate cancers by the use of PSA for screening of
prostate cancer. It is however possible that the Kallikrein locus SNPs
contribute to PSA levels and prostate cancer independently, and
thus further studies are needed to delineate the role of Kallikrein
locus SNPs in prostate cancer etiology.
In conclusion, this work represents an in-depth study of genetic
variation in the Prostinogen/KLK15 gene. Our investigation has
made maximum utilization of existing databases and bioinformatic
software programs to shortlist SNPs for inclusion in a prostate
cancer genetic association study. We identified rs2659056 to be
associated with tumor aggressiveness in a QLD sample set and this
result was replicated in two large international cohorts. Additional
experimental evidence is required to replicate our results and to
understand the effects of this variant on the regulation of KLK15
expression, and its relationship with PSA levels and possible
confounders introduced by case and control selection criteria
based on PSA levels.
Materials and Methods
Ethics Statement
The study protocol was approved by the Human Research
Ethics Committees of QUT, QIMR, the Mater Hospital (for
Table 2. Association between KLK15 SNPs and prostate cancer risk in the QLD and PLCO study groups.
Qld DATA PLCO Cancer Screening Trial (CGEMS)
SNP
a Control Cases OR (95% CI) P value
b OR (95% CI) p value
c,d
rs2659053
GG 542 (39.5) 348 (35.0)
GA 615 (44.9) 486 (48.8) 1.25 (1.04–1.50) 0.050 1.02 (0.83–1.25) 0.839
AA 214 (15.6) 161 (16.2) 1.19 (0.92–1.52)
rs35711205
CC 914 (66.0) 618 (61.3)
CG 410 (29.6) 350 (34.7) 1.27 (1.06–1.52) 0.027 1.16 (0.90–1.49) 0.253
GG 60 (4.3) 40 (4.0) 0.96 (0.63–1.46)
aSNP identifier based on NCBI dbSNP; SNPs are included in the region of the KLK15 gene including 2 kb of transcription start sites.
bThe result of 2-d.f. test based on logistic regression in the Queensland study adjusted for age as continuous variable.
cImputed from 1000 Genomes project data and PLCO genotyped data, where actual genotype data not available, [27]; allelic OR and p values are presented.
dThe result of 2-d.f. test based on logistic regression in the PLCO study adjusted for age in five-year intervals, study center, and three eigenvectors to control population
stratification in an incident density sampling strategy.
doi:10.1371/journal.pone.0026527.t002
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Alexandra Hospital and the Cancer Council Queensland. All
participants gave written informed consent.
Study Participants
Queensland (QLD) prostate cancer cases and
controls. QLD prostate cancer cases (N=1,011) were
ascertained from two studies. In the first cross-sectional study,
men with prostate cancer were recruited within two years of
diagnosis through urologist referrals from three hospitals in
Brisbane, Queensland (N=154, age range 51–87 years) [17]. In
the second longitudinal randomized control trial study entitled
Prostate Cancer Supportive Care and Patient Outcomes Project
(ProsCan): men newly diagnosed with prostate cancer from 26
private practices and 10 public hospitals in Queensland were
directly referred to ProsCan at the time of diagnosis by their
treating clinician (N=857, age range 43–88 years) [30]. All cases
had histopathologically confirmed prostate cancer, following
presentation with an abnormal serum PSA and/or lower urinary
tract symptoms. Male controls (N=1,405) with no personal history
of prostate cancer were recruited from two different sources. Male
blood donors were recruited through the Australian Red Cross
Table 3. Association between KLK15 shortlisted SNPs and prostate tumour aggressiveness, using a case-case analysis.
SNP Genotype
Non-aggressive
cases (GS,7)
Aggressive
cases (GS$7) OR (95 CI)
a P value
rs2659058 TT 118 (46.6) 277 (45.4)
CT 108 (42.7) 269 (44.1) 1.01(0.81–1.27) 0.91
CC 27 (10.7) 64 (10.5)
rs3212810 CC 143 (56.7) 349 (57.2)
TC 97 (38.5) 229 (37.5) 1.00(0.78–1.28) 1.00
TT 12 (4.8) 32 (5.2)
rs3745522 GG 145 (56.2) 353 (57.7)
GT 97 (37.6) 218 (35.6) 0.98(0.77–1.24) 0.88
TT 16 (6.2) 41 (6.7)
rs2659056 TT 111 (44.0) 343 (56.2)
TC 118 (46.8) 228 (37.4) 0.70(0.56–0.89) 0.003
CC 23 (9.1) 39 (6.4)
rs266851 CC 180 (69.2) 398 (65)
CT 74 (28.5) 195 (31.9) 1.22(0.92–1.61) 0.17
TT 6 (2.3) 19 (3.1)
rs2659055 TT 57 (22.5) 153 (25.7)
TC 140 (55.3) 308 (51.7) 0.97(0.78–1.21) 0.80
CC 56 (22.1) 135 (22.7)
rs190552 TT 151 (59.7) 372 (61.1)
CT 89 (35.2) 214 (35.1) 0.88(0.68–1.14) 0.34
CC 13 (5.1) 23 (3.8)
rs266855 CC 133 (51.6) 297 (48.7)
CT 109 (42.2) 253 (41.5) 1.18(0.93–1.48) 0.17
TT 16 (6.2) 60 (9.8)
rs2739442 GG 98 (38.4) 200 (32.8)
GA 114 (44.7) 280 (46) 1.19(0.97–1.46) 0.09
AA 43 (16.9) 129 (21.2)
rs2659053 GG 83 (32.9) 217 (35.6)
GA 117 (46.4) 298 (48.9) 0.86(0.7–1.07) 0.17
AA 52 (20.6) 94 (15.4)
rs2569746 AA 100 (39.5) 212 (34.8)
TA 109 (43.1) 303 (49.8) 1.04(0.84–1.29) 0.71
TT 44 (17.4) 94 (15.4)
rs35711205 CC 159 (61.2) 381 (62.2)
CG 87 (33.5) 211 (34.4) 0.90(0.7–1.16) 0.42
GG 14 (5.4) 21 (3.4)
aThe result of trend test based on logistic regression adjusted for age as continuous variable.
Bold represents significant p values.
doi:10.1371/journal.pone.0026527.t003
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The second control group comprised men randomly selected from
the Australian Electoral Roll (voting is compulsory in Australia),
age-matched (in 5 year groups; age range 54–90 years) and area-
code matched to ProsCan cases (N=569). Clinical and
epidemiologic characteristics of participants are detailed in Table 1.
Replication set. Analyses were based on samples genotyped
in first and second stages of an UK/Australian GWAS, collected
as previously described [24,28], together with a third stage
involving a further 4,574 (3,041 with data on Gleason score) cases
and 4,165 controls. Briefly, stage 1 prostate cancer cases
(N=2,017) were from the UK Genetic Prostate Cancer Study
(UKGPCS) and were selected on the basis of either a diagnosis at
age #60 years (N=1,291) or a first- or second-degree family
history of prostate cancer (N=726). Male controls (N=2,001)
included men aged $50 years with a PSA of #0.5 ng/ml,
geographically matched to the prostate cancer cases selected
through the ProtecT study.
Stage 2 comprised prostate cancer cases and controls from the
UK and Australia. The former were ascertained through the
UKGPCS as above (N=332) and through a systematically
collected series from prostate cancer clinics in the Urology unit
at the Royal Marsden NHS Foundation Trust (N=1,680) over a
14-year period. UK controls were identified through the
UKGPCS study (N=449) and the ProtecT study (limited to those
men with a PSA of ,10 ng/ml; N=1,712). Self-reported ‘‘non-
white’’ men were excluded. The Australian stage 2 cases were
ascertained from three studies: (i) a population based series of
prostate cancer cases identified from the Victorian Cancer
Registry since 1999, diagnosed at ,56 years (Early Onset Prostate
Cancer Study (EOPCFS); N=526); (ii) a population-based case-
control study based on cases diagnosed in Melbourne and Perth
(Risk Factors for Prostate Cancer Study (RFPCS); N=594); and
(iii) a prospective cohort study of 17,154 men aged 40–69 years at
recruitment in 1990–1994 (Melbourne Collaborative Cohort
Study (MCCS); N=190). For RFPCS, cases were identified from
Table 4. Association between KLK15 rs2659056 SNP and prostate tumour aggressiveness in five different study groups, using a
case-case analysis.
SNP Controls
Non-aggressive
cases (GS,7)
Aggressive
cases (GS$7)
OR (95 CI) Aggressive
vs Non-aggressive) P value
Australian dataset (n
cases=862, n
control=1375)
a
TT 758 (55.1) 111 (44.0) 343 (56.2)
TC 527 (38.3) 118 (46.8) 228 (37.4) 0.70 (0.56–0.89) 0.003
CC 90 (6.5) 23 (9.1) 39 (6.4)
UK GWAS Stage 1 (n
cases=1232 n
control=1894)
b
TT 1166 (61.6) 368 (55.1) 298 (52.8)
TC 650 (34.3) 250 (37.4) 224 (39.7) 1.06 (0.89–1.26) 0.54
CC 78 (4.1) 50 (7.5) 42 (7.4)
UK GWAS Stage 2 (n
cases=2343, n
control=3936)
b
TT 2164 (55) 680 (55.3) 606 (54.4)
TC 1510 (38.4) 478 (38.9) 443 (39.8) 1.03 (0.9–1.17) 0.71
CC 262 (6.7) 71 (5.8) 65 (5.8)
UK GWAS Stage 3 (n
cases=3041, n
control=4165)
b
TT 2346 (56.3) 771 (52.3) 875 (56.0)
TC 1536 (36.9) 584 (39.6) 595 (37.9) 0.87 (0.78–0.98) 0.020
CC 283 (6.8) 119 (8.0) 97 (6.1)
CGEMS (n
cases=1148; n
control=1145)
c
TT 624 (54.5) 259 (53.0) 359 (54.5)
TC 443 (38.7) 194 (39.7) 261 (39.6) 0.93 (0.77–1.12) 0.43
CC 78 (6.8) 36 (7.4) 39 (5.9)
Combined Results (n
cases=8,626; n
control=12,515)
c
TT 7058 (56.4) 2189 (53.2) 2481 (55.0)
TC 4666 (37.3) 1624 (39.5) 1751 (38.8) 0.92 (0.86–0.98) 0.017
CC 791 (6.3) 299 (7.3) 282 (6.2)
Combined Results with studies selected on heterogeneity test (n
cases=5,051; n
control=6,685)
c
TT 3728 (55.8) 1141 (51.5) 1577 (55.6)
TC 2506 (37.5) 896 (40.5) 1084 (38.2) 0.85 (0.77–0.93) 2.7610
24
CC 451 (6.7) 178 (8.0) 175 (6.2)
aThe result of trend test based on logistic regression adjusted for age as continuous variable.
bUK dataset adjusted for study group (categorical) and age (continuous.)
cAdjusted for study group and age as categorical variable.
n
cases=total no of patients; n
control=total no of controls.
doi:10.1371/journal.pone.0026527.t004
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prostate cancer (excluding tumors with Gleason scores of less than
5) and were diagnosed at ,70 years with sampling stratified by age
at diagnosis. Australian stage 2 controls were either recruited as
part of the RFPCS study, in which they were identified through
the Australian Electoral Roll and frequency matched to the age
distribution of the RFPCS cases (N=509), or were a random
sample from the MCCS cohort (N=760).
Stage 3sampleswereselectedfromUKGPCSasforstage 1and 2;
from Studies of Epidemiology and Risk factors in Cancer Heredity
(SEARCH), a case-control study based on region covered by the
Eastern UKCancer Registry and Information Centre (ECRIC); and
from the Australian epidemiological studies as in stage 2.
We also included data from the Cancer Genetic Markers of
Susceptibility (CGEMS) study, a GWAS of 1,117 prostate cancer
cases oversampled for aggressive disease and 1,105 controls, drawn
from the European PLCO study (http://cgems.cancer.gov/).
KLK15 Sequencing and Genotyping
Methods used for DNA preparation and genotyping have been
described previously [18]. Briefly, germline DNA was extracted
from peripheral blood using the Qiagen DNA isolation kit for all
men recruited in the study. Four primer sets were designed to
amplify selected regions chosen from the in silico analysis of the
putative KLK15 promoter region. For promoter sequencing, primer
sets were designed using NETprimer (http://www.premierbiosoft.
com/netprimer/netprlaunch/etprlaunch.html) and purchased
from Sigma Proligo (Sigma Proligo, NSW, Australia). Ten ng of
germline DNA from 20 aggressive prostate cancer patients was
amplified in a 20 uL polymerase chain reaction (PCR) mix
optimised for each primer as described previously [26].
SNPs in the Queensland (QLD) dataset was genotyped using
iPLEX Gold assays on the Sequenom MassARRAY platform
(Sequenom, San Diego, USA), as described previously [18].
Quality control parameters included a combination of cases and
controls on each plate, genotype call rates .95%, $98%
concordance between duplicates (.5% duplicates on each plate),
four negative (H2O) controls per 384-well plate and Hardy-
Weinberg Equilibrium P values.0.05.
Genotyping of the replication sample sets was performed as part
of a published genome-wide association study (GWAS) [25,28].
The Stage 3 genotyping was done using an Illumina Golden Gate
Assay (http://www.illumina.com).
Statistical Analysis
Covariates, including age at diagnosis, screening history and first-
degree familyhistoryofprostate cancer,were examined tosee ifsuch
factors changed the risk estimates by $10%. After these tests, only
age at diagnosis (continuous variable) and study group (as a
categorical variable) was included in the final models. Predictive
Analytics Software (PASW) Statistics version 17.0.2 (SPSS Inc,
Chicago, Illinois) wasused for allanalyses, unless otherwisespecified.
Comparisons of genotype distribution and their association with
prostate cancersusceptibilityandclinical datawereperformedunder
co-dominant and linear models, using chi-square and logistic
regression analysis, and odds ratios and p were values calculated.
Prostate cancer cases with tumor Gleason scores $7 were classified
as aggressive. For the combined analysis, genotype and phenotype
data (disease status, Gleason score, age, family history etc) was
obtained for different studies and was analysed as per above after
adjusting for study groups and age (as a categorical variable). The
extent ofheterogeneity across studies wasmeasured by the likelihood
ratio test. After applying Bonferroni correction, a p value of ,0.004
was considered significant to account for the 12 SNPs studied.
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Figure S1 Linkage Disequilibrium map generated by Haploview
4.2. Frequency data was generated for the control male individuals
and the LD map was plotted. SNPs in bold were found to have
frequencies.0.05.
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Figure S2 Forest plot showing the association between
rs2659056 and prostate tumour aggressiveness in five different
study groups, using a case-case analysis.
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analysis with risk of prostate cancer. SNPs in the KLK15
gene derived from the HapMap database and those by in silico
prediction methods were genotyped in male control, and the minor
allele frequency (MAF) and HWE were calculated using Haploview
4.2 in healthy males. SNPs in bold were shortlisted for genotyping
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